The efficacy of T2PEX+TM and T2PEX in abrogating tumour development in vivo, we surmise, is due to their ability to prevent MT1-MMP-driven cleavage and remodelling of the cell matrices by the implanted cancer cells. This evidence concerns the gene MMP14 and cancer.